[go: up one dir, main page]

GB202019874D0 - New compounds and methods - Google Patents

New compounds and methods

Info

Publication number
GB202019874D0
GB202019874D0 GBGB2019874.3A GB202019874A GB202019874D0 GB 202019874 D0 GB202019874 D0 GB 202019874D0 GB 202019874 A GB202019874 A GB 202019874A GB 202019874 D0 GB202019874 D0 GB 202019874D0
Authority
GB
United Kingdom
Prior art keywords
methods
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2019874.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Bio Ltd
Original Assignee
BenevolentAI Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BenevolentAI Bio Ltd filed Critical BenevolentAI Bio Ltd
Priority to GBGB2019874.3A priority Critical patent/GB202019874D0/en
Publication of GB202019874D0 publication Critical patent/GB202019874D0/en
Priority to PCT/GB2021/053319 priority patent/WO2022129913A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2019874.3A 2020-12-16 2020-12-16 New compounds and methods Ceased GB202019874D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2019874.3A GB202019874D0 (en) 2020-12-16 2020-12-16 New compounds and methods
PCT/GB2021/053319 WO2022129913A1 (en) 2020-12-16 2021-12-16 Alkyne derivatives as inhibitors of c-abl

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2019874.3A GB202019874D0 (en) 2020-12-16 2020-12-16 New compounds and methods

Publications (1)

Publication Number Publication Date
GB202019874D0 true GB202019874D0 (en) 2021-01-27

Family

ID=74188946

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2019874.3A Ceased GB202019874D0 (en) 2020-12-16 2020-12-16 New compounds and methods

Country Status (2)

Country Link
GB (1) GB202019874D0 (en)
WO (1) WO2022129913A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0106631D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
WO2007002441A1 (en) 2005-06-24 2007-01-04 Emory University Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection
US20140045826A1 (en) * 2011-04-07 2014-02-13 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
CN108473476B (en) * 2016-10-13 2021-02-19 深圳市塔吉瑞生物医药有限公司 Alkynyl heterocyclic compounds for inhibiting protein kinase activity
CN114340734A (en) * 2019-06-24 2022-04-12 博善人工智能生物科技有限公司 New compounds and methods

Also Published As

Publication number Publication date
WO2022129913A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
GB201903827D0 (en) New compounds and methods
GB202015035D0 (en) New compounds and methods
GB202015044D0 (en) New compounds and methods
GB201903832D0 (en) New compounds and methods
SG11202108625WA (en) Compounds and methods for reducing kcnt1 expression
GB202010429D0 (en) Methods
GB202004094D0 (en) New compounds and uses
GB202007434D0 (en) Methods
GB202111184D0 (en) Methods
GB202100352D0 (en) New methods
GB202019767D0 (en) Compostitions and methods
GB202104422D0 (en) Methods
GB201913110D0 (en) New compounds and methods
GB202007928D0 (en) New uses and methods
GB202113594D0 (en) New compounds and methods
GB202113588D0 (en) New compounds and methods
GB202009064D0 (en) Compounds and methods of use
GB202109069D0 (en) Compounds and method
GB202115389D0 (en) Methods
GB202113589D0 (en) New compounds and methods
GB202019876D0 (en) New compounds and methods
GB202019877D0 (en) New compounds and methods
GB202019874D0 (en) New compounds and methods
GB202015048D0 (en) New compounds and methods
GB202015039D0 (en) New compounds and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)